JAK Janus Kinase

Cat.No.	Name	Information
M3030	S-Ruxolitinib	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820	Tofacitinib	Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660	AZ 960	AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646	AG490	AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733	TG101348	TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787	INCB18424	Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo.
M5944	Ruxolitinib phosphate	Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616	Tofacitinib citrate	Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346	Filgotinib	Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044	AZD1480	AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M49560	Axltide	Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).
M49559	AT9283 lactic acid	AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM).
M49558	Antitumor agent-123	Antitumor agent-123 effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC50 values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively.
M49556	25-Deacetylcucurbitacin A	25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor.
M49555	JAK-IN-11	JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment.
M49554	Lorpucitinib	Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease.
M49553	JAK2 JH2 binder-1	JAK2 JH2 binder-1 is a potent and selective JAK2 JH2 binder, with a Kd of 37.1 nM.
M49552	Povorcitinib phosphate	Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules.
M49551	JAK-IN-5 hydrochloride	JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
M49550	JAK-IN-23	JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB.
M49549	GS-829845	GS-829845 is a major, active metabolite of Filgotinib.
M49548	VVD-118313	VVD-118313 is a potent, selective JAK1 inhibitor.
M49547	Pumecitinib	Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.
M43416	SJ1008030 TFA	SJ1008030 TFA is a JAK2 PROTAC which selectively degrades JAK2.
M42103	DPP	DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand.
M42102	STAT3-IN-18	STAT3-IN-18 is a platinum (IV) complex with an axial ligand derived from sandalwood.
M41718	JAK-IN-28	JAK-IN-28 is a JAK inhibitor.
M41717	JAK-IN-29	JAK-IN-29 is a potent JAK inhibitor.
M41716	JAK kinase-IN-1	JAK kinase-IN-1 is a JAK inhibitor.
M41715	JAK-STAT-IN-1	JAK-STAT-IN-1 is a selective JAK-STAT inhibitor.

By Signaling Pathways

By Product Type

Signaling Pathways

JAK Janus Kinase

Get to Know Us

Customer Support

Resources

Contact Us